Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Inovio Pharmaceuticals Inc (INO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Inovio's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.6800 -0.5200    -5.10%
19/04 - Closed. Currency in USD ( Disclaimer )
After Hours
9.5100
-0.1700
-1.7562%
23:39:46 - Real-time Data
  • Volume: 345,907
  • Bid/Ask: 9.5100 / 9.6800
  • Day's Range: 9.5450 - 10.2000
Type:  Equity
Market:  United States
Inovio 9.6800 -0.5200 -5.10%

Inovio Company Profile

 
Read the Inovio company profile to learn more about the business and the management team. View Inovio Pharmaceuticals Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

122

Equity Type

ORD

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Contact Information

Address 660 West Germantown Pike Suite 110
Plymouth Meeting, 19462
United States
Phone 267 440 4200
Fax -

Top Executives

Name Age Since Title
Simon X. Benito 76 2003 Independent Chairman of Board of Directors
Wendy L. Yarno 68 2017 Independent Director
Jacqueline E. Shea 56 2019 CEO, President & Director
Roger D. Dansey 66 2021 Independent Director
David B. Weiner 67 2000 Chairman of the Scientific Advisory Board & Director
Rafi Ahmed - 2018 Member of Scientific Advisory Board
Lota S. Zoth 63 2019 Independent Director
Stanley A. Plotkin 90 2009 Member of Scientific Advisory Board
Anthony W. Ford-Hutchinson - 2012 Member of Scientific Advisory Board
Ann Calby Miller 64 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

INO Price Commentary

Write your thoughts about Inovio Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mohammad Mousa
Mohammad Mousa Jul 24, 2023 15:25
Saved. See Saved Items.
This comment has already been saved in your Saved Items
any observations ?
Jonny Tr
Jonny Tr Jan 04, 2022 8:00
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Another Theranos!
Parker Casper
Parker Casper Jun 16, 2021 21:08
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the price is gonna touch usd. 7.50 by end of this weeke and then shoot up to usd.14.00 by early next month. Gurustocks
Stan Di
Stan Di Feb 13, 2021 15:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.appliedclinicaltrialsonline.com/view/running-a-covid-vaccine-trial
Abhishek Jain
Abhishek Jain Sep 28, 2020 16:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Zero target?
Kaine Pritchett
Kaine Pritchett Sep 28, 2020 16:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yeah i think you should go all in and short it to zero - go for it
Nurullah Sonmez
Nurullah Sonmez Aug 11, 2020 13:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what is going on
Jonny Tr
Jonny Tr Aug 11, 2020 13:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
a $2B+ company with that is consistently losing money for years?
Roy Martinez
Roy Martinez Jul 25, 2020 8:37
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Still seems to be a two pace forward and one back stock much like Moderna.
Alex White
Alex White Jul 21, 2020 9:47
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone know the target price?
Fong Hoa
Fong Hoa Jul 21, 2020 9:47
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$75 if they get funding?
Redouane Elisaoui
Redouane Elisaoui Jul 09, 2020 15:10
Saved. See Saved Items.
This comment has already been saved in your Saved Items
mark my words this one and Novavax will win the race
Pravin Dand
Pravin Dand Jul 02, 2020 17:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Force buying till 24
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email